Overview

Study of PI-88 in Patients With Advanced Melanoma

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medigen Biotechnology Corporation